Clinical Trial Update: BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating a CD19-targeting CAR-T cell therapy with BCOR and ZC3H12 gene knock-outs for relapsed/refractory B-cell lymphoma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• BCOR/ZC3H12 knockout CD19-targeting CAR-T cell therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: B Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING